Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Early Breast Cancer Diagnosis With a Heat-Sensing Bra

Early Breast Cancer Diagnosis With a Heat-Sensing Bra

When it comes to cancer, prevention before it develops undoubtedly produces the best outcomes. Although half of cancers arise from preventable causes,some cancers cannot be prevented. In this situation, early diagnosis and methods that can enable it, cancer screening, are the most valuable approaches. In oncology we witness the development of new early-detection tools every day. One is a special biosensor braaiming to detect breast cancer early.

Designed in Mexico and called EVA, this biosensor bra attempts early recognition of abnormal breast growths through thermal (heat) sensing and artificial intelligence as its methods. Julián Ríos Cantú, CEO of its developer Higia Technologies, says EVA is not only easy to use for early detection but also fills gaps in existing mammography screening.

You May Be Interested:

Today, women have several options for breast cancer screening : breast ultrasound (less specific than other options) or breast MRI (more expensive) can be chosen. The standard option, however, for women aged 45 and older, annually or every other year, is mammography. But all 3 methods require seeing a doctor or, in mammography, exposure to radiation, albeit at a low dose.

How Does the Thermal Biosensor Bra EVA Work?

The user places thermal-sensing cups into a sports bra, opens the EVA Health App, follows the instructions and waits 60 minutes while the cups collect thermal data. EVA then sends the data via Bluetooth, and the artificial intelligence application analyzes the results to provide an assessment. If EVA detects a risky situation, it recommends seeing a healthcare professional for further investigation.

Although analysis of personal health data by artificial intelligence or the possibility of the device being hacked may not appeal to some people, Cantú says Higia Technologies has taken steps to protect user data, including advanced encryption.

So far, EVA has undergone, in Mexico, clinical trials that produced sensitivity of 87.9 percent and specificity of 81.7 percent. The company has already sold 5000 devices in Mexico.

Interest in EVA continues to grow. Cantú has received various awards, including Mexico's Presidential Medal for Science and Technology in 2017, and EVA was named one of "2018's Most Promising Businesses" by Forbes Magazine Mexico.

Looking ahead, the company wants to enter the US market and plans to begin clinical trials with Stanford Medicine in October 2018, lasting around a year. The company's medical director says the device will continue the FDA approval process after these trials.

Final pricing outside Mexico remains unclear. Sales in Japan outside Mexico are planned to begin during 2018. However, Cantú says he wants the product to be as affordable and accessible as possible. He therefore says it could be a first option for women in developing countries with limited access to cancer screening tests.

Conclusion

Early diagnosis will remain the most important strategy for reducing cancer deaths in the future. Efforts in this direction will not be wasted. Asked whether early detection should use external sensors like these or internal biomarkers and sensors, I would choose the latter. This development might have been exciting 20 years ago, but considering the pace of scientific discoveries and technological change, I cannot call it a tremendous invention today. Let us watch its practical use and clinical implications together.

Sources

Sarah Wells
Y Combinator invests in non-invasive breast cancer screening bra EVA
techcrunch.com - 18 Aug 2018

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Early Breast Cancer Diagnosis With a Heat-Sensing Bra

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy